Article
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care.
Molecular oncology - 1 May 2022
Hedtke Maren, Pessoa Rejas Rodrigo, Froelich Matthias F, Ast Volker, Duda Angelika, Mirbach Laura, Costina Victor, Martens Uwe M, Hofheinz Ralf-Dieter, Neumaier Michael, Haselmann Verena
Abstract excerpt
The analysis of circulating tumor DNA (ctDNA) is at the threshold of implementation into standard care for colorectal cancer (CRC) patients. However, data about the clinical utility of liquid profiling (LP), its acceptance by clinicians, and its integration into clinical workflows in real-world settings remain limited. Here, LP tests requested as part of routine care since 2016 were retrospectively evaluated....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.